Giovedì 24 Gennaio 2019 | 14:03

NEWS DALLA SEZIONE

Rome
'Shoot Salvini' says anarchist graffiti in Milan

'Shoot Salvini' says anarchist graffiti in Milan

 
Strasbourg
ILVA emissions endanger locals' health says Strasbourg Court

ILVA emissions endanger locals' health says Strasbourg Court

 
Strasbourg
Italy violated Knox's right to defence - Strasbourg

Italy violated Knox's right to defence - Strasbourg

 
Rome
Innovative Rome transplant on 20-month-old Alex successful

Innovative Rome transplant on 20-month-old Alex successful

 
Davos
Assess consequences if growth deteriorates - Moscovici

Assess consequences if growth deteriorates - Moscovici

 
Strasbourg
Disparity in access to abortion in Italy says Strasbourg

Disparity in access to abortion in Italy says Strasbourg

 
Rome
Italian govt says measures ready for no-deal Brexit

Italian govt says measures ready for no-deal Brexit

 
Rome
League, M5S reach deal on offshore drilling

League, M5S reach deal on offshore drilling

 
On board the papal plane
Pope pays homage to late Russian journo

Pope pays homage to late Russian journo

 
Milan
Pets to be buried with owners in Lombardy

Pets to be buried with owners in Lombardy

 
Rome

Doctors urge Fico to suspend no-vax conference

 

Rome

Study shows eyedrops can repair vision damage from tumors

'Results open a new road' says researcher

Study shows eyedrops can repair vision damage from tumors

Rome, January 14 - A clinical study conducted at Rome's Gemelli Hospital showed that an eyedrop with nerve growth factor (NGF) can partially repair vision damage in patients with glioma, a brain tumor that damages the nerves that transmit images from the retina to the brain. The study, conducted on 18 patients ages 2-23 years old, was led by Antonio Chiaretti, Benedetto Falsini and Riccardo Riccardi together with the National Research Council (CNR). "We tested the efficacy and safety of NGF, administered as an eyedrop through the conjunctiva," said Chiaretti. He said this method enabled the NGF to directly penetrate the visual pathways where it could exert its action without causing any collateral damage. Of the 10 patients who received the NGF eyedrops versus the eight who received a placebo, the NGF patients demonstrated significant improvement on various vision exams conducted before and after the study, as well as a significant increase of their visual field. The results improved their quality of life enough that they were able to be more autonomous in their daily activities. The placebo group demonstrated a progression of the pathology with a worsening of visual acuity. "Our results open a new road into the possible therapeutic use of NGF in treating serious visual deficiencies caused by gliomas of the visual pathways, encouraging research not only in this specific field of application, but also in other types of injuries that involve vision mechanisms, such as degenerative retinopathy and glaucoma," said Falsini. Neurologist Rita Levi-Montalcini was awarded the Nobel Prize in Medicine in 1986 together with her colleague Stanley Cohen for their discovery of NGF.

Lascia il tuo commento

Condividi le tue opinioni su

Caratteri rimanenti: 400